...
首页> 外文期刊>Circulation journal >Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.
【24h】

Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.

机译:血管紧张素Ⅱ1型受体阻滞剂与二氢吡啶类钙拮抗剂治疗高血压患者阵发性房颤的随机研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called "upstream therapy", which refers to the blockade of upstream modifying elements (renin - angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate. METHODS AND RESULTS: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring. CONCLUSIONS: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.
机译:背景:节律与速率控制的大型试验无法证明现有抗心律失常药物的有效性,因此,现在需要一种更有效,更安全的房颤(AF)治疗方法。一种候选物是所谓的“上游疗法”,其是指对导致心律不齐的底物起作用的上游修饰元素(肾素-血管紧张素系统,血管紧张素,氧化应激等)的阻断。方法和结果:日本房颤心律管理试验II(J-RHYTHM II研究)是对血管紧张素II 1型阻滞剂(坎地沙坦)和二氢吡啶类钙阻滞剂(氨氯地平)与抗血栓治疗相结合的随机比较评估,作为抗心律失常疗法,用于治疗与高血压相关的阵发性房颤(PAF)。为了测试该疗法的有效性,本研究将通过每日对苯二酚监测显示使用坎地沙坦或氨氯地平治疗1年内无症状和有症状PAF的复发率。结论:J-RHYTHM II研究将追踪400名患有PAF和高血压的患者,这些患者在日本大约50个地点接受了治疗,并将提供临床重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号